Sinemet
Sinemet Price range: $ 46,00 through $ 623,00
Back to products
Singulair
Singulair Price range: $ 42,00 through $ 502,00

Sinequan

Price range: $ 52,00 through $ 399,00

Sinequan is a highly effective medication primarily used to manage symptoms of depression and anxiety. It belongs to the tricyclic antidepressant class and works by balancing neurotransmitters in the brain to improve mood and emotional stability. This treatment is particularly beneficial for individuals experiencing psychoneurotic disorders accompanied by tension or apprehension. In addition to addressing mood-related concerns, it helps alleviate physical symptoms often associated with prolonged emotional distress. By targeting the underlying causes of persistent sadness, Sinequan supports a more balanced and positive daily life.

Active substance: Doxepin
SKU: Sinequan Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Sinequan belongs to a class of central nervous system agents known as tricyclic antidepressants (TCAs). It is prescribed by healthcare providers primarily for the treatment of depression and anxiety associated with psychoneurotic disorders.

As a prescription-only oral drug regulated by the United States Food and Drug Administration (FDA), Sinequan must be taken strictly under medical supervision. Dosage determination and clinical monitoring are necessary to optimize therapeutic benefits while minimizing potential adverse effects.

Product Summary

Drug name Sinequan
Active ingredient Doxepin hydrochloride
Therapeutic class Tricyclic antidepressant (TCA)
Dosage form Oral capsule, oral concentrate
Route of administration Oral
Prescription status Prescription only (Rx)

Prescribing Information and Pharmacological Profile

How the drug works

Doxepin hydrochloride exerts its primary therapeutic effect by inhibiting the neuronal reuptake of serotonin and norepinephrine at the presynaptic membrane in the central nervous system. This pharmacological action increases neurotransmitter availability in the synaptic cleft, facilitating improved monoaminergic signaling. In addition, doxepin exhibits potent antagonist activity at histamine H1 receptors, which accounts for its marked sedative properties. The compound also displays anticholinergic activity through muscarinic receptor blockade and antagonizes alpha-1 adrenergic receptors, contributing to both its clinical utility and its characteristic side-effect profile.

Main uses

Sinequan is FDA-approved for the management of psychoneurotic patients suffering from depression, anxiety, or both. Specific indications include anxiety associated with alcoholism, organic disease, or psychotic depressive conditions, as well as endogenous and reactive depression. The medication helps address associated clinical features such as sleep disturbance, apprehension, and functional physical complaints. In clinical practice, healthcare providers may evaluate doxepin for off-label applications, such as chronic neurogenic pain management or severe refractory pruritus in dermatologic conditions; however, these off-label uses require distinct clinical rationale and specialist monitoring.

Dosing schedule

Dosing of Sinequan must be individualized based on symptom severity, patient age, and clinical responsiveness. For adult patients presenting with mild to moderate depression or anxiety, the standard initial daily dosage ranges from 75 mg to 150 mg. This total daily dose may be administered either in divided doses throughout the day or as a single dose at bedtime. In severe cases, titrated dosages up to 300 mg daily may be prescribed under direct clinical supervision. Elderly patients generally require lower initial doses, often starting at 25 mg to 50 mg daily, to mitigate risks associated with reduced metabolic clearance and increased sensitivity to anticholinergic effects. Oral capsules should be swallowed whole with fluid, while oral concentrate preparations must be diluted immediately prior to ingestion using water, milk, or fruit juice.

What happens in the body

Following oral administration, doxepin hydrochloride is rapidly absorbed from the gastrointestinal tract, achieving peak plasma concentrations within two to four hours. The drug undergoes extensive first-pass hepatic metabolism primarily mediated by cytochrome P450 isoenzymes, including CYP2D6, CYP2C19, and CYP1A2. Demethylation yields its primary active metabolite, N-demethyldoxepin (nordoxepin), which contributes significantly to the overall therapeutic profile. The elimination half-life of doxepin ranges from 8 to 24 hours, whereas the half-life of nordoxepin is longer, ranging from 28 to 31 hours. Both doxepin and its active metabolite are extensively bound to plasma proteins and are excreted principally by the kidneys as glucuronide conjugates.

Compatibility with other medicines

Concomitant administration of Sinequan with monoamine oxidase inhibitors (MAOIs) is strictly contraindicated due to the potential for hyperpyretic crises, severe seizures, and fatal hypertensive episodes. A minimum washout period of 14 days must elapse between discontinuing an MAOI and initiating doxepin therapy. Combining doxepin with other central nervous system depressants, including benzodiazepines, sedating antihistamines, or opioids, can exacerbate central sedation and respiratory depression. Co-administration of strong CYP2D6 inhibitors (such as fluoxetine, paroxetine, or quinidine) may increase doxepin plasma levels, elevating the risk of adverse drug reactions. Sympathomimetic agents and anticholinergic drugs may also interact cumulatively with doxepin, enhancing cardiovascular or anticholinergic toxicity.

Patient Safety and Practical Management

Adverse reactions

Adverse effects of Sinequan primary stem from its central nervous system, anticholinergic, and cardiovascular activity. Sedation and drowsiness are common, particularly during the initial phase of treatment. Anticholinergic side effects include dry mouth (xerostomia), blurred vision, constipation, and urinary retention. Cardiovascular effects may encompass orthostatic hypotension, sinus tachycardia, dizziness, and electrocardiographic changes. Less common reactions include weight gain, excessive sweating, gastrointestinal upset, tremor, and altered endocrine function. Patients experiencing marked cognitive changes, cardiac palpitations, or severe dizziness should consult their physician promptly.

What to avoid while taking it

Patients undergoing treatment with Sinequan should completely avoid alcohol consumption. Ethanol potentiates the central nervous system depressant and sedative actions of doxepin, severely impairing psychomotor performance, motor coordination, and mental alertness. Furthermore, oral concentrate formulations should not be mixed with carbonated beverages or grape juice due to compatibility considerations. Patients should also exercise caution regarding high heat exposure, as anticholinergic activity can suppress sweating and impair body temperature regulation.

If you skip a dose

If a dose of Sinequan is missed, it should be taken as soon as remembered, provided it is not close to the scheduled time for the next dose. If the next dose is due shortly, the missed dose should be skipped and the regular administration schedule resumed. Patients must not double the dose or take extra medication to compensate for a missed dose. When Sinequan is prescribed as a single daily bedtime dose, a missed night-time dose should typically be skipped in the morning to avoid excessive daytime drowsiness.

Special populations

Sinequan carries a FDA boxed warning regarding an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults up to age 24 during initial treatment phases. Use in pediatric populations is generally not established. Elderly individuals demonstrate heightened sensitivity to orthostatic hypotension, confusion, and urinary retention, requiring cautious dosing and periodic reassessment. During pregnancy, Sinequan should be used only if the potential benefits justify the potential risks to the fetus, as tricyclic compounds cross the placental barrier. Doxepin is excreted into human breast milk and can cause sedation or respiratory depression in nursing infants; therefore, breastfeeding during treatment is usually discouraged.

Storage and expiration

Sinequan capsules and liquid concentrate should be stored at controlled room temperature between 68°F and 77°F (20°C to 25°C), with permitted excursions between 59°F and 86°F (15°C to 30°C). The container must be kept tightly closed and protected from light and excess moisture. Storage in high-humidity areas, such as bathrooms, should be avoided. All medications must be stored securely out of reach of children and pets. Expired or unneeded medication should be disposed of through community drug take-back programs or according to established FDA medication disposal protocols.

Important precautions

Patients starting Sinequan should be monitored closely for clinical worsening, agitation, or unusual changes in behavior. Due to its anticholinergic properties, doxepin should be prescribed with extreme caution in patients with a history of narrow-angle glaucoma, severe urinary retention, or benign prostatic hyperplasia. Patients with cardiovascular disease, including recent myocardial infarction, heart failure, or conduction abnormalities, require thorough cardiac assessment prior to initiating therapy. Abrupt discontinuation of long-term doxepin therapy should be avoided, as rapid withdrawal can produce symptoms such as nausea, headache, and sleep disturbances; gradual dose tapering under clinical supervision is recommended.

Common Questions

How long does it usually take to notice therapeutic effects from Sinequan?

While sedative effects and relief from acute anxiety may occur early in treatment, the antidepressant therapeutic response typically develops gradually. Patients usually require two to three weeks of consistent daily dosing to experience significant improvement in depressive symptoms. It is essential to continue the prescribed dosage as directed even if immediate mood improvement is not observed.

Does Sinequan cause changes in body weight?

Weight changes, particularly weight gain, are recognized potential adverse effects associated with long-term tricyclic antidepressant therapy, including doxepin. This effect is thought to be mediated through antihistaminic and metabolic pathways. Patients concerned about weight alterations should discuss nutritional and monitoring strategies with their prescribing physician.

Is it safe to drive or operate machinery while taking Sinequan?

Sinequan frequently causes drowsiness and impaired psychomotor coordination, especially during initial dosage titration. Patients should refrain from driving, operating heavy machinery, or engaging in potentially hazardous tasks until they understand how the drug individually affects their alertness and motor response.

What signs indicate an overdose of Sinequan, and what action should be taken?

An overdose of doxepin is a serious medical emergency. Symptoms of toxicity include severe drowsiness, low blood pressure, rapid or irregular heartbeat, dilated pupils, muscle rigidity, severe confusion, and convulsions. Emergency medical services (call 911 in the United States) or a regional poison control center should be contacted immediately if an overdose is suspected.

Can Sinequan be stopped abruptly once symptoms resolve?

Abrupt cessation of Sinequan following prolonged administration can trigger withdrawal symptoms, including insomnia, headache, malaise, and gastrointestinal distress. Discontinuation should always be conducted under medical supervision using a gradual dose reduction schedule to ensure patient safety and comfort.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

10mg

,

25mg

,

75mg

Package

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία